Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Lung Transplant Rejection - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H2 2016, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape. Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively.Lung Transplant Rejection. Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology). - The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lung Transplant Rejection Overview 6 Therapeutics Development 7 Pipeline Products for Lung Transplant Rejection - Overview 7 Lung Transplant Rejection - Therapeutics under Development by Companies 8 Lung Transplant Rejection - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Lung Transplant Rejection - Products under Development by Companies 12 Lung Transplant Rejection - Companies Involved in Therapeutics Development 13 Apeptico Forschung und Entwicklung GmbH 13 Dompe Farmaceutici S.p.A. 14 Kamada Ltd. 15 Novartis AG 16 Proteo, Inc. 17 Quark Pharmaceuticals, Inc. 18 Lung Transplant Rejection - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 alpha-1 proteinase inhibitor (human) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 everolimus - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FX-06 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 QPI-1024 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 QPLI-1 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 R-554 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 R-801 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 reparixin - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 solnatide - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 tiprelestat - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Lung Transplant Rejection - Dormant Projects 61 Lung Transplant Rejection - Product Development Milestones 62 Featured News & Press Releases 62 Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 62 Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury 63 Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 64 Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 65 Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 65 Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 66 Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables Number of Products under Development for Lung Transplant Rejection, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2016 13 Lung Transplant Rejection - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 14 Lung Transplant Rejection - Pipeline by Kamada Ltd., H2 2016 15 Lung Transplant Rejection - Pipeline by Novartis AG, H2 2016 16 Lung Transplant Rejection - Pipeline by Proteo, Inc., H2 2016 17 Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Lung Transplant Rejection - Dormant Projects, H2 2016 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.